Title

Vitality-ALS a Phase III Trial of Tirasemtiv a Selective Fast Skeletal Muscle Troponin Activator as a Potential Treatment for Patients With Amyotrophic Lateral Sclerosis: Study Design and Baseline Characteristics

Department

neurology

Document Type

Article

Abstract

Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo on respiratory function and other functional measures in patients with amyotrophic lateral sclerosis (ALS). This study was designed to confirm and extend results from a large phase IIb trial and maximize tolerability with a slower dose escalation. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled, parallel-group study in ALS patients. Participants who tolerated two weeks of open-label tirasemtiv (125 mg twice a day) were randomized 3:2:2:2 to placebo or one of three target total daily dose levels of tirasemtiv (250, 375, or 500 mg). Participants randomized to tirasemtiv escalated their dose every two weeks to their target dose level or maximum tolerated dose. The primary outcome measure was change in slow vital capacity from baseline to 24 weeks. Secondary endpoints assessed the effect of tirasemtiv on muscle strength and certain respiratory milestones of disease progression. A four-week randomized withdrawal phase followed 48 weeks of treatment to evaluate the possibility of sustained benefit or rebound decline. Results: Data collection will be complete in the fourth quarter of 2017. Conclusions: VITALITY-ALS was a phase III trial designed to evaluate the efficacy, safety, and tolerability of tirasemtiv in ALS.

Medical Subject Headings

neurology

Publication Date

2018

Publication Title

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN

21678421

Volume

19

Issue

43528

First Page

259

Last Page

266

Digital Object Identifier (DOI)

10.1080/21678421.2018.1426770

This document is currently not available here.

Share

COinS